Translational Research

One of the very unique aspects of The Neuro is the integration of fundamental biological research with applied research in human physiology and mechanisms of human disease.

Clinical Research Unit

The Neuro’s Clinical Research Unit (CRU) evaluates the efficacy of new drugs and treatment regimens. Many patients come to because they want to have access to the newest medications and diagnostic procedures. Since 1992, 140 trials have been conducted within the CRU, giving over 1000 patients suffering from multiple sclerosis, epilepsy, stroke, ALS or brain cancer access to new treatments.  The CRU has access to the most advanced medical technology available today. The CRU conducts clinical trials sponsored by pharmaceutical companies or granting agencies such as the National Institutes of Health (NIH) in the USA. All clinical trials are approved by Health Canada (and the FDA if conducted in USA) and have passed a rigorous review by The Neuro's Research Ethics Board or the McGill Institutional Review Board. All experimental medications used in clinical trials have been tested for safety.

The CRU is dedicated to:
• Aiding the advancement of neuroscience through clinical research
• Participating in clinical trials to identify new or more effective treatments.
• Supplying study subjects with the best quality of care.
• Providing high quality data to sponsors and investigators.

For more information, please visit the CRU website.

Experimental Therapeutics Program

The importance of multidisciplinary translational research in medicine is well recognized. The MNI is expanding such research through the Experimental Therapeutics Program. This program will complement and extend basic laboratory initiatives into pre-clinical and clinical studies of human biology, including normal physiology as well as disease states. Through this initiative, physicians and researchers are expediting the development of new therapies for neurological and auto-immune diseases, while gaining novel insights into disease processes. Using a core laboratory, they integrate fundamental research with rigorous studies on human biological samples derived from well-characterized healthy volunteers and from patients with neurological diseases, both before and during treatment with experimental therapies.

Investigators and trainees active in this program develop and study collections of human biological samples, develop and apply bioassays to these samples, and utilize bioinformatics tools as they target new therapies. They will further define the relationships between clinical and neuro-imaging outcomes and these novel biological measures. The Neuro’s Experimental Therapeutics Program (ETP) is  designed as a complete ‘bench to bedside and back’ platform and expedites the translation of fundamental discoveries to the human disease context. Understanding the translational implications of novel fundamental discoveries is paramount.  The ETP provides researchers at The Neuro with a bridge to technology that facilitates therapy development for use in humans.

For information, contact:
Sandeep Vanamala
514-398-1487
sandeep [dot] vanamala [at] mcgill [dot] ca (Email)
For more information, please visit the ETP website.